乳腺癌患者中细胞色素b561表达与生存预后的关系

Relationships between cytochrome b561 expressions and survival prognosis in breast cancer patients

目的探索细胞色素b561(cytochromeb561,CYB561)在乳腺癌中的表达水平和预后价值。方法通过免疫组化法,比较76例乳腺癌患者和40例良性乳腺疾病患者的CYB561表达水平,采用Kaplan-Meier法估计生存期并进行log-rank检验,通过COX回归分析探讨乳腺癌生存预后的影响因素。结果免疫组织化学评分结果显示,与正常组织相比,乳腺癌组织中CYB561的表达水平较高(t=7.33,P=0.005),且病理Ⅲ级乳腺癌患者中CYB561的表达水平高于病理Ⅰ~Ⅱ级(t=12.32,P<0.001);4种乳腺癌亚型的CYB561表达水平进行方差分析后显示,4组间差异有统计学意义(F=229.247,P<0.001),多重比较结果显示,与LuminalA型、LuminalB型和HER2阳性患者相比,TNBC患者的CYB561表达水平升高(t=14.054、15.899、12.538,P均<0.001)。此外,CYB561表达水平在雌激素受体、孕激素受体状态中的差异有统计学意义(t=7.54、2.51,P均<0.001)。Kaplan-Meier生存分析表明,CYB561高表达组5年总生存期和5年无病生存期短于CYB561低表达组[(41.09±1.50)个月vs(52.56±1.74)个月、(25.39±1.99)个月vs(33.42±2.34)个月,χ^(2)=7.780、5.219,(P=0.005、0.022)]。COX回归分析显示,CYB561表达水平(HR=0.244,95%CI=0.085~0.697,P=0.008)是乳腺癌患者生存预后的影响因素。结论CYB561可能在乳腺癌的发生发展中起重要作用,其表达水平可作为乳腺癌患者诊断和预后评估的潜在生物标志物。

Objective To investigate the expression levels and prognostic value of cytochrome b synthase(CYB)561 in breast cancer.Methods The expression level of CYB561 was compared between 76 patients with breast cancer and 40 patients with benign breast disease by immunohistochemistry.The Kaplan-Meier method was used to estimate the survival and log-rank test was performed.Determinants of survival prognosis of breast cancer were explored via COX regression analysis.Results The results of immunohistochemical scoring showed that the expression level of CYB561 was higher in breast cancer tissues than in normal ones(t=7.33,P=0.005),and in patients with pathological grade Ⅲ breast cancer than in those who pathological grades Ⅰ-Ⅱ(t=12.32,P<0.001).The difference in expression levels of CYB561 in the four breast cancer subtypes subjected to ANOVA between the four groups was statistically significant(F-229.247,P<0.001).Multiple comparisons showed that CYB561 expression levels were elevated in TNBC patients compared with Luminal A,Luminal B and HER2-positive patients(t=14.054,15.899,12.538,all P<0.001).In addition,the difference in CYB561 expression levels in estrogen receptor and progesterone receptor status was statistically significant(t=7.54,2.51,both P<0.001)The results of Kaplan-Meier survival analyses showed that patients in the CYB561 high-expression group showed shorter 5-year overall survival and 5-year disease-free survival than those in the CYB561 low expression group[(41.09±1.50)months vs(52.56±1.74)months,(25.39±1.99)months vs(33.42±2.34)months,(χ^(2)=7.780,5.219,P=0.005,0.022)].The results of COX regression analyses showed that the expression level of CYB561(HR=0.244,95%CI=0.085~0.697,P=0.008)could make a difference to the survival prognosis of breast cancer patients.Conclusion CYB561 may play an important role in the development of breast cancer,and its expression level can be used as a potential biomarker for prognosis evaluation and diagnosis of breast cancer patients.